CHAD                                                 ovarian(114)
 _________________________________________________________________
  cytoxan......... 600 mg/sqm IV day 1.
  hexamethylmelami 150 mg/sqm/day orally from day 8 to day 22.
  adriamycin...... 25 mg/sqm IV day 1.
  cisplatin....... 50 mg/sqm IV day 1.
  FREQUENCY....... Repeat cycle every 28 days.

  reference...
    Vogl SE.  Pagano M.  Kaplan BH.  Greenwald E.  Arseneau J. 
    Bennett B. Cis-platin based combination chemotherapy for 
    advanced ovarian cancer. High overall response rate with 
    curative potential only in women with small tumor burdens. 
    Cancer.  51(11):2024-30, 1983 Jun 1. 
  abstract...
    Thirty-eight women with advanced ovarian cancer were given 
    monthly cycles of intravenous cyclophosphamide, Adriamycin 
    (doxorubicin) and cis-platin, and oral hexamethylmelamine. Of 
    26 with tumor which would be evaluated for response, 42% had 
    complete remission and 50% partial remission. Median time to 
    disease progression from entry for all 38 patients was 13 
    months, and median survival 23.5 months. The bulk of tumor at 
    the time chemotherapy was begun was the only significant 
    prognostic factor for time to disease progression and 
    survival. Of the seven women surviving free of disease a 
    median of three years later, five had no mass greater than 2 
    centimeters in diameter at entry. Toxicity was predominantly 
    myelosuppression and vomiting, with mild peripheral neuropathy 
    in 27% and no significant renal or cardiac toxicity. The 
    response rate of 92% is much higher than that previously 
    reported with melphalan, and the survival considerably longer. 
    The toxicity is acceptable, given the substantial improvement 
    in results.